Opemifene API

Name	Opemifene
Chinese name	奥培米芬
Cas Number	-
Source	India
Qualifications	USDMF/-/-/-/-

Opemifene was developed by Shionogi. It was first approved for marketing by the US Food and Drug Administration (FDA) on February 26, 2013, and was later approved by the European Medicines Agency (EMA) on January 15, 2015. Approval of listing. This product is one of the active metabolites of toremifene and a new type of selective estrogen receptor modulator. It has both estrogen and anti-estrogen effects, showing tissue selectivity. Opemifene can prevent bone loss caused by estrogen reduction in animal models, and can inhibit the growth of human breast cancer MCF7 cells and tumors, and can also inhibit the growth of breast tumors caused by dimethylbenzanthracene (DMBA) . Opemifene has weak estrogenic and anti-estrogen effects on the uterus, but has significant estrogenic effects on bones. In addition, Opemifene does not cause liver toxicity caused by tamoxifen. Therefore, Opemid has been further studied to treat osteoporosis and atrophy of the reproductive system in postmenopausal women. The approval of new indications for Opemifene can help more menopausal women and will provide an oral option for women who prefer non-hormonal alternatives.

Hot Tags: opemifene api, China, suppliers, manufacturers, factory, customized, price, pricelist, in stock, Lifitegrast API, Temozolomide API, Bosentan API, Solinasine Succinate API, Fondaparinux API, Pabxilib API

• Previous: Dronedarone Hydrochloride API
• Next: Pabisstat API